Introduction {#Sec1}
============

Adenosine, a naturally occurring nucleoside, is involved in a wide variety of physiological and pathophysiological processes \[[@CR1]\]. Adenosine mediates these effects through the activation of at least four human receptor subtypes (P1), belonging to the superfamily of G protein-coupled receptors, which have been recently cloned \[[@CR2]\] and classified as A~1~, A~2A~, A~2B~ and A~3~ \[[@CR3]\]. The subtypes are classified on the bases of coupling to second messengers and pharmacological profiles for agonists and antagonists. In fact, A~1~ and A~3~ adenosine receptor subtypes are linked to inhibition of adenylyl cyclase and A~2A~ and A~2B~ subtypes are linked to stimulation of the same enzyme \[[@CR4]\].

In particular, A~2B~ receptors have been implicated in several physiological functions such as the regulation of mast cell secretion \[[@CR5], [@CR6]\], gene expression \[[@CR5], [@CR7], [@CR8]\], cell growth \[[@CR9]\] and intestinal functions. A~2B~ receptors may also play a role in asthma, since they mediate mast cell degranulation from human mast cells and are present in high density in human blood eosinophils \[[@CR10], [@CR11]\]. For this reason A~2B~ antagonists could be considered potential antiasthmatic agents \[[@CR10]--[@CR12]\]. While the A~1~, A~2A~ and A~3~ adenosine receptors have been pharmacologically characterized through the use of highly potent and selective agonists and/or antagonists, an accurate investigation of the pathophysiological role of A~2B~ receptors is precluded due to the lack of very selective ligands \[[@CR13]\]. On the other hand, only recently radiolabelled adenosine antagonists have been used for binding assays at the A~2B~ receptor subtype \[[@CR1]\]. Recently, xanthine derivatives, such as compounds **1** and **2** in Fig. [1](#Fig1){ref-type="fig"}, have been proposed as potent and selective adenosine receptor antagonists \[[@CR14], [@CR15]\]. On the other hand, in the non-xanthine family poor results have been obtained in recent years. However, mention should be made of the pyrazolo-triazolo-pyrimidine derivative **3**, which showed promising binding affinity at the A~2B~ adenosine receptor although the level of selectivity vs the human (h) A~3~ subtype was still poor \[[@CR16]\]. Very recently, a bipyrimidyl derivative **4** has been proposed as an A~2B~ adenosine receptor antagonist, with affinity in the same range of compound **3,** while the selectivity vs the other receptor subtypes was found to be significantly better \[[@CR17]\] (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Structures and binding profile (K~i~ nM) of some A~2B~ adenosine receptor antagonists

A structural analysis of the derivatives **1** and **3** clearly shows the presence of bulky substituents such as aryloxyacetylamino-phenyl groups at the 8 position (compound **1**) and arylacetyl moiety at the N5 position (compound **3**).

On the other hand, in recent years a number of substituted adenines have been synthesized and tested at the four adenosine receptor subtypes, demonstrating that the introduction of different substituents at the 2, 8 and 9 positions of the adenine core resulted in high-affinity antagonists with distinct receptor selectivity profile \[[@CR18]--[@CR22]\]. At the A~2B~ receptor the derivatives bearing an ethyl in the 9 position and linear chains in the 2 position showed potency in the μM range, while the presence of sterically hindered substituents in the same positions was detrimental for the potency. Furthermore, substitution of the 9-ethyl group with a propyl chain seems to favour the interaction with human A~2B~ receptors \[[@CR21]\].

Hence, on the basis of the results obtained with compound **3**, introduction of a bulky substituent on the *N*^6^ amino group of the adenine and 2-chloroadenine moiety could increase potency and selectivity for the human A~2B~ adenosine receptor subtypes.

Hence, bulky substituents such as arylacetyl or aryloxyphenylacetyl moieties were introduced on the *N*^6^ amino group of compounds **5** and **6** to obtain derivatives **7**--**14**, with the aim of finding a new class of A~2B~ antagonists (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Structures of designed compounds

Chemistry {#Sec2}
=========

The designed compounds (**5--14**) have been synthesized as summarized in Schemes [1](#Sch1){ref-type="fig"} and [2](#Sch2){ref-type="fig"}. The starting 9-propyladenine (**5**) \[[@CR23]\] was obtained by alkylation of commercially available adenine (**15**) with propyliodide in the presence of potassium carbonate. Flash chromatography led to the desired 9-substituted isomer **5** as the major product (yield 79%) together with the 7-isomer **5a** (yield 9%). Isomeric structure of compounds **5** and **5a** was assigned on the bases of 1D-^1^H-NOE difference spectra. In fact, irradiation of both CH~2~ groups of the propylic chain in compound **5a** gave a NOE at both H-C(8) and 6-NH~2~ groups, demonstrating the 7 position as the alkylation site. On the contrary, a NOE at both H-C(8) and H-C(2), and not at the 6-NH~2~ group in compound **5**, upon saturation of CH~2~ groups of the propylic chain, confirmed the 9 position as the alkylation site. Scheme 1**a** Synthesis of 9-propyladenine; **b** Synthesis of 2-chloro-9-propyladenine. Reagents: i: DMF, K~2~ CO~3~, propyliodide, RT; ii: liq. NH~3~, sealed tube, RTScheme 2Reagents: i: CDI, dry THF, reflux

The 2-chloro derivative **6** was obtained by alkylation of commercially available 2,6-dichloropurine (**16**) with propyliodide, using the same procedure utilized for compound **5**, to afford the 9-substituted isomer **17** as the major product (yield 75%) along with the 7-isomer **17a** (yield 10%) \[[@CR24]\]. \[^1^H\]-NMR spectra of **17** and **17a** in CDCl~3~ are in agreement with those reported in the literature \[[@CR24]\]; in the experimental part \[^1^H\]-NMR spectra of the same compounds are reported using dimethyl sulfoxide (DMSO) as the solvent. Compound **17** was reacted with liquid ammonia in a sealed tube at room temperature (RT) overnight to give the 2-chloro-9-propyladenine (**6**) \[[@CR24]\] (Scheme [1](#Sch1){ref-type="fig"}).

Final compounds **7--14** were obtained by condensation of amino compounds **5** or **6** with the appropriate acid **18--22** \[[@CR25]\] in the presence of carbonyldiimidazole in tetrahydrofurane (THF) at reflux for 18 h (Scheme [2](#Sch2){ref-type="fig"}).

Results and discussion {#Sec3}
======================

All the compounds were evaluated at the human recombinant adenosine receptors, stably transfected into Chinese hamster ovary (CHO) cells, utilizing radioligand binding studies (A~1~, A~2A~, A~3~) or adenylyl cyclase activity assay (A~2B~). Receptor binding affinity was determined using \[^3^H\]CCPA (2-chloro-*N*^6^-cyclopentyladenosine) as the radioligand for A~1~ receptors, whereas \[^3^H\]NECA (5'-*N*-ethylcarboxamidoadenosine) was used for the A~2A~ and A~3~ subtypes. In the case of A~2B~ receptors K~i~ values were calculated from IC~50~ values determined by inhibition of NECA-stimulated adenylyl cyclase activity. K~i~ values are in μM, with 95% confidence intervals in parentheses \[[@CR26]\]. The results of binding and cyclase activity studies are reported in Table [1](#Tab1){ref-type="table"}. Table 1Biological profile of synthesized compounds **5--14**^a^Displacement of specific \[^3^H\]-CCPA binding at human A~1~ receptors expressed in CHO cells. ^b^Displacement of specific \[^3^H\]-NECA binding at human A~2A~ receptors expressed in CHO cells. ^c^K~i~ values of the inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells expressing human A~2B~ receptors. ^d^Displacement of specific \[^3^H\]-NECA binding at human A~3~ receptors expressed in CHO cells.

All the tested compounds **5--14** showed affinities at the human A~1~, A~2A~ and A~3~ adenosine receptors in the μM range without significant levels of selectivity. At A~2B~ receptors most compounds were found to be inactive when tested at a concentration up to 100 μM (K~i~ values \> 30 μM). It is quite evident that the introduction of phenylacetic or aryloxyphenylacetic moieties at the *N*^6^ position of 9-propyladenine (**5**) or of 2-chloro-9-propyladenine (**6**) to give compounds **7--14** modifies the binding profile of the derivatives, although without significantly increasing binding affinity (Table [1](#Tab1){ref-type="table"}). On the other hand, the same substitutions were found to be detrimental for the activity at the A~2B~ receptor subtype. In fact, the *N*^6^-unsubstituted derivative **6** proved to be the most potent of the series with K~i~ A~2B~ = 11 μM.

The effect of the chlorine at the 2 position on binding affinity at the adenosine receptors it is not univocal, depending on the receptor subtype and/or on the substituent in *N*^6^. Analysis of the binding profile of the *N*^6^-unsubstituted derivatives in more detail revealed that the presence of a chlorine atom at the 2 position (compound **6**) increased the affinity (A~1~, A~2A~ and A~3~) and potency (A~2B~) at adenosine receptors two- to threefold compared with the unsubstituted analogue **5**.

A quite similar profile could be observed when a 4-bromophenylacetic group was introduced at the *N*^6^ position (compare compound **8** with **7**).

An opposite effect of the chlorine atom was detected at A~1~, A~2B~ and A~3~ receptors when a bulkier substituent, such as the 4-aryloxyphenylacetic chain, was introduced at the *N*^6^ position. In fact, this kind of combination significantly reduced or did not modify the A~1~ and A~3~ affinity and the A~2B~ potency (**9**: K~i~ A~1~ = 1.4 μM, K~i~ A~2B~ \> 30 μM, K~i~ A~3~ = 5.3 μM vs **10**: K~i~ A~1~ = 26 μM, K~i~ A~2B~ \> 30 μM, K~i~ A~3~ = 4.9 μM and **12**: K~i~ A~1~ = 13 μM, K~i~ A~2B~ = 22 μM, K~i~ A~3~ = 10 μM vs **13**: K~i~ A~1~ = 22 μM, K~i~ A~2B~ \> 30 μM, K~i~ A~3~ = 19 μM).

However, in all cases, the presence of a chlorine atom in the 2 position favoured the interaction with the A~2A~ subtype (compare A~2A~ affinity of **5**, **7**, **9** and **12** with **6**, **8**, **10** and **13**, respectively), while the presence of any substituent on the *N*^6^ position seems to somewhat reduce the affinity. In fact the compound endowed with the highest A~2A~ affinity proved to be the 2-chloro-9-propyladenine (**6**: K~i~ A~2A~ = 2.2 μM). These findings are in agreement with previous observations related to adenosine analogues strongly suggesting that the introduction of substituents in the *N*^6^ position dramatically reduces the A~2A~ affinity \[[@CR27]--[@CR32]\].

Nevertheless, it should be underlined that the presence of a bulky chain at the *N*^6^ position significantly increased (20- to 70-fold) the affinity at the A~1~ and A~3~ subtypes in comparison with 9-propyladenine (**9**: K~i~ A~1~ = 1.4 μM and **11**: K~i~ A~3~ = 1.4 μM vs **5**: K~i~ A~1~ = 24 μM and K~i~ A~3~ \> 100 μM).

This increase of affinity seems also to be modulated by the substituent on the aryloxyphenylacetic group; in fact, substitution with a lipophilic bromine (**9**) or methyl group (**11**) at the *para* position is responsible for the increased A~1~ and A~3~ receptor affinity, respectively, while the presence of a hydrogen (**12**) or a methoxy group (**14**) did not positively influence the binding profile.

Conclusions {#Sec4}
===========

In conclusion the study herein presented, although it did not reach the proposed goal of obtaining A~2B~ adenosine receptor antagonists, increased knowledge of the structure-activity relationships in adenine derivatives.

Moreover, it was demonstrated that the introduction of bulky substituents at the *N*^6^ position of adenine derivatives significantly increased the affinity at the A~1~ and A~3~ adenosine receptors, while the presence of a chlorine atom in the 2 position favoured the interaction with the A~2A~ subtype. These results demonstrated that, although the synthesized compounds were found to be quite inactive at the human A~2B~ subtype, adenine is a useful template for further development of simplified adenosine receptor antagonists with distinct receptor selectivity profiles, opening up new chances to design structurally simplified A~1~ and A~3~ adenosine receptor antagonists.

Experimental section {#Sec5}
====================

Chemistry {#Sec6}
---------

**General:** melting points were determined with a Büchi apparatus and are uncorrected. ^1^H NMR spectra were obtained with Varian VXR 300 MHz spectrometer; δ in ppm, *J* in Hz. All exchangeable protons were confirmed by addition of D~2~O. Thin layer chromatography (TLC) was carried out on precoated TLC plates with silica gel 60 F-254 (Merck). For column chromatography, silica gel 60 (Merck) was used. Elemental analyses were determined on Fisons Instruments Model EA 1108 CHNS-O model analyser and are within ± 0.4% of theoretical values.

### 9-Propyladenine (***5***) *and 7-propyladenine* (***5a***) {#Sec7}

To a solution of adenine (**15**) (0.5 g, 3.7 mmol) in dry DMF (10 ml), under nitrogen, K~2~CO~3~ (0.83 g, 5.97 mmol) and propyliodide (0.433 ml, 4.44 mmol) were added. The mixture was stirred at RT for 16 h, then the solvent was removed under reduced pressure and the crude purified by flash chromatography (CHCl~3~-MeOH 98:2) to afford **5** \[[@CR23]\] and **5a** (yield 79 and 9%, respectively) as white solids, after crystallization from CH~3~OH.

**5**: m.p. 173--175°C. ^1^H-NMR (DMSO-*d*~6~) δ 0.85 (t, 3H, *J* = 7.4, CH~3~); 1.82 (m, 2H, *CH*~*2*~-CH~3~); 4.11 (t, 2H, *J* = 7.0, CH~2~-N); 7.21 (bs, 2H, NH~2~); 8.15 (s, 2H, H-2 and H-8). Anal. Calcd. for C~5~H~5~N~5~ (177.2) C, 54.22; H, 6.26; N, 39.52; found: C, 54.54; H, 6.71; N, 39.33.

**5a**: m.p. \>250°C. ^1^H-NMR (DMSO-*d*~6~) δ 0.86 (t, 3H, *J* = 7.3, CH~3~); 1.91 (m, 2H, *CH*~*2*~-CH~3~); 4.26 (t, 2H, *J* = 7.0, CH~2~-N); 7.75 (s, 1H, H-2); 7.85 (bs, 2H, NH~2~); 8.34 (s, 1H, H-8). Anal. Calcd. for C~5~H~5~N~5~ (177.2) C, 54.22; H, 6.26; N, 39.52; found: C, 54.45; H, 6.45; N, 39.45.

### 2,6-Dichloro-9-propyl-9H-purine (***17***) *and 2,6-dichloro-7-propyl-9H-purine* (***17a***) {#Sec8}

To a solution of 2,6-dichloropurine (**16**) (1 g, 5.29 mmol) in dry DMF (14 ml), under nitrogen, K~2~CO~3~ (1.18 g, 6.61 mmol) and propyliodide (0.59 ml, 6.08 mmol) were added. The mixture was stirred at RT overnight, then the solvent was removed under reduced pressure and the crude purified by flash chromatography (cC~6~H~12~-EtOAc 75:25) to afford **17** and **17a** as white solids (yield 75 and 10%, respectively) \[[@CR24]\].

**17**: m.p. 58--59°C; ^1^H-NMR (DMSO- *d*~6~) δ 0.86 (t, 3H, *J* = 7.5 Hz, CH~2~*CH*~*3*~), 1.85 (m, 2H, *CH*~*2*~CH~3~), 4.21 (t, 2H, *J* = 7.0 Hz, N-CH~2~), 8.76 (s, 1H, H-8). Anal. Calcd. for C~8~H~8~Cl~2~N~4~ (231.1) C, 41.58; H, 3.49; N, 24.25. Found: C, 41.85; H, 3.70; N, 24.10.

**17a**: m.p. 103--105°C; ^1^H-NMR (DMSO-*d*~6~) δ 0.87 (t, 3H, *J* = 7.4 Hz, CH~2~*CH*~*3*~), 1.84 (m, 2H, *CH*~*2*~CH~3~), 4.40 (t, 2H, *J* = 7.2 Hz, N-CH~2~), 8.89 (s, 1H, H-8). Anal. Calcd. for C~8~H~8~Cl~2~N~4~ (231.1) C, 41.58; H, 3.49; N, 24.25. Found: C, 41.75; H, 3.55; N, 24.19.

### 2-Chloro-9-propyladenine (***6***) {#Sec9}

Liquid ammonia (5 ml) and compound **17** (0.46 g, 1.97 mmol) were poured into a sealed tube and the resulting mixture was stirred at RT overnight. Ammonia was evaporated and the crude purified by flash chromatography (CHCl~3~-MeOH 99:1) to give **6** \[[@CR24]\] as a white solid (yield 75%) m.p. 224--226°C. ^1^H-NMR (DMSO-*d*~*6*~) δ 0.84 (t, 3H, *J* = 7.3 Hz, CH~2~*CH*~*3*~), 1.79 (m, 2H, *CH*~*2*~CH~3~), 4.05 (t, 2H, *J* = 7.2 Hz, N-CH~2~), 7.72 (s, 2H, NH~2~), 8.15 (s, 1H, H-8). Anal. Calcd. for C~8~H~10~ClN~5~ (211.7) C, 45.40; H, 4.76; N, 33.09. Found: C, 45.75; H, 4.80; N, 32.87.

### General procedure for the preparation of the *N*^6^-acylaminoadenine (***7***--***14***) {#Sec10}

A solution in dry THF (4 ml) of the appropriate acid (**18--22**) (0.46 mmol) and carbonyldiimidazole (83 mg, 0.51 mmol) was poured at reflux under nitrogen for 1 h. Then the amino compound **5** or **6** (0.46 mmol) was added and the resulting mixture was refluxed overnight. The solvent was removed under reduced pressure and the crude purified by flash chromatography to afford the desired final compounds **7--14**.

### 6-\[(4-Bromophenyl)acetyl\]amino-9-propyladenine (***7***) {#Sec11}

Eluent for chromatography CHCl~3~-MeOH 95:5; yield 59%, white solid; m.p. 149--151°C (dec.); ^1^H-NMR (DMSO-*d*~6~): δ 0.83 (t, 3H, *J* = 7.2 Hz, CH~2~*CH*~*3*~), 1.84 (m, 2H, *CH*~*2*~CH~3~), 3.89 (s, 2H, CH~2~-CO), 4.19 (t, 2H, *J* = 7.1 Hz, N-CH~2~), 7.30 (d, 2H, *J* = 8.4 Hz, H-Ph), 7.51 (d, 2H, *J* = 8.4 Hz, H-Ph), 8.47 (s, 1H, H-8), 8.62 (s, 1H, H-2), 10.91 (s, 1H, NH). Anal. Calcd. for C~16~H~16~BrN~5~O (374.2) C, 51.35; H, 4.31; N, 18.71. Found: C, 51.65; H, 4.80; N, 18.50.

### 6-\[(4-Bromophenyl)acetyl\]amino-2-chloro-9-propyladenine (***8***) {#Sec12}

Eluent for chromatography CHCl~3~-cC~6~H~12~ 80:20; yield 26%, white solid; m.p. 164--166°C; ^1^H-NMR (DMSO-*d*~6~): δ 0.84 (t, 3H, *J* = 7.5 Hz, CH~2~*CH*~*3*~), 1.83 (m, 2H, *CH*~*2*~CH~3~), 3.88 (s, 2H, CH~2~-CO), 4.15 (t, 2H, *J* = 6.9 Hz, N-CH~2~), 7.30 (d, 2H, *J* = 8.4 Hz, H-Ph), 7.53 (d, 2H, *J* = 8.4 Hz, H-Ph), 8.50 (s, 1H, H-8), 11.25 (s, 1H, NH). Anal. Calcd. for C~16~H~15~BrClN~5~O (408.7) C, 47.02; H, 3.70; N, 17.14. Found: C, 47.49; H, 3.83; N, 17.40.

### 6-\[(4-(4-Bromobenzyloxy)phenyl)acetyl\]amino-9-propyladenine (***9***) {#Sec13}

Eluent for chromatography CHCl~3~-MeOH 95:5; yield 58%, white solid; m.p. 154--156°C; ^1^H-NMR (DMSO-*d*~6~): δ 0.85 (t, 3H, *J* = 7.5 Hz, CH~2~*CH*~*3*~), 1.85 (m, 2H, *CH*~*2*~CH~3~), 3.82 (s, 2H, CH~2~-CO), 4.21 (t, 1H, *J* = 7.0 Hz, N-CH~2~), 5.07 (s, 2H, CH~2~-O), 6.95 (d, 2H, *J* = 8.8 Hz, H-Ph), 7.27 (d, 2H, *J* = 8.4 Hz, H-Ph), 7.40 (d, 2H, *J* = 8.4 Hz, H-Ph), 7.58 (d, 2H, *J* = 8.4 Hz, H-Ph), 8.48 (s, 1H, H-8), 8.62 (s, 1H, H-2), 10.81 (s, 1H, NH). Anal. Calcd. for C~23~H~22~BrN~5~O~2~ (480.4) C, 57.51; H, 4.62; N, 14.58. Found: C, 57.99; H, 4.66; N, 14.55.

### 6-\[(4-(4-Bromobenzyloxy)phenyl)acetyl\]amino-2-chloro-9-propyladenine (***10***) {#Sec14}

Eluent for chromatography CHCl~3~-cC~6~H~12~-MeOH 50:48:2; yield 14%, white solid; m.p. 176--178°C; ^1^H-NMR (DMSO-*d*~6~): δ 0.81 (t, 3H, *J* = 7.5 Hz, CH~2~*CH*~*3*~), 1.79 (m, 2H, *CH*~*2*~CH~3~), 3.76 (s, 2H, CH~2~-CO), 4.12 (t, 2H, *J* = 7.4 Hz, N-CH~2~), 5.03 (s, 2H, CH~2~-O), 6.92 (d, 2H, *J* = 8.6 Hz, H-Ph), 7.22 (d, 2H, *J* = 8.4 Hz, H-Ph), 7.36 (d, 2H, *J* = 8.4 Hz, H-Ph), 7.54 (d, 2H, *J* = 8.4 Hz, H-Ph), 8.46 (s, 1H, H-8), 11.11 (s, 1H, NH). Anal. Calcd. for C~23~H~21~BrClN~5~O~2~ (514.8) C, 53.66; H, 4.11; N, 13.60. Found: C, 53.75; H, 4.25; N, 13.29.

### 6-\[(4-(4-Methylbenzyloxy)phenyl)acetyl\]amino-9-propyladenine (***11***) {#Sec15}

Eluent for chromatography CHCl~3~-cC~6~H~12~-MeOH 70:28:2; yield 35%, white solid; m.p.131--132°C; ^1^H-NMR (DMSO-*d*~6~): δ 0.83 (t, 3H, *J* = 7.3 Hz, CH~2~*CH*~*3*~), 1.84 (m, 2H, *CH*~*2*~CH~3~), 2.28 (s, 3H, *CH*~*3*~-Ph), 3.80 (s, 2H, CH~2~-CO), 4.20 (t, 2H, *J* = 7.1 Hz, N-CH~2~), 5.02 (s, 2H, CH~2~-O), 6.93 (d, 2H, *J* = 8.4 Hz, H-Ph), 7.24 (m, 6H, H-Ph), 8.47 (s, 1H, H-8), 8.62 (s, 1H, H-2), 10.83 (s, 1H, NH). Anal. Calcd. for C~24~H~25~N~5~O~2~ (415.5) C, 69.38; H, 6.06; N, 16.86. Found: C, 69.74; H, 6.35; N, 16.54.

### 6-\[(4-Benzyloxyphenyl)acetyl\]amino-9-propyladenine (***12***) {#Sec16}

Eluent for chromatography CHCl~3~-MeOH 97:3; yield 52%, white solid; m.p. 121--123°C; ^1^H-NMR (DMSO-*d*~6~): δ 0.83(t, 3H, *J* = 7.5 Hz, CH~2~*CH*~*3*~), 1.84 (m, 2H, *CH*~*2*~CH~3~), 3.80 (s, 2H, CH~2~-CO), 4.19 (t, 2H, *J* = 7.1 Hz, N-CH~2~), 5.07 (s, 2H, CH~2~-O), 6.95 (d, 2H, *J* = 8.4 Hz, H-Ph), 7.25 (d, 2H, *J* = 8.8 Hz, H-Ph), 7.37 (m, 5H, H-Ph), 8.47 (s, 1H, H-8), 8.62 (s, 1H, H-2), 10.82 (s, 1H, NH). Anal. Calcd. for C~23~H~23~N~5~O~2~ (401.5) C, 68.81; H, 5.77; N, 17.44. Found: C, 68.97; H, 5.89; N, 17.35.

### 6-\[(4-Benzyloxyphenyl)acetyl\]amino-2-chloro-9-propyladenine (***13***) {#Sec17}

Eluent for chromatography CHCl~3~-MeOH 99:1; yield 17%, white solid; m.p. 150--152°C; ^1^H-NMR (DMSO-*d*~6~): δ 0.84 (t, 3H, *J* = 7.3 Hz, CH~2~*CH*~*3*~), 1.82 (m, 2H, *CH*~*2*~CH~3~), 3.79 (s, 2H, CH~2~-CO), 4.14 (t, 2H, *J* = 7.0 Hz, N-CH~2~), 5.07 (s, 2H, CH~2~-O), 6.95 (d, 2H, *J* = 8.6 Hz, H-Ph), 7.25 (d, 2H, *J* = 8.4 Hz, H-Ph), 7.37 (m, 5H, H-Ph), 8.49 (s, 1H, H-8), 11.16 (s, 1H, NH). Anal. Calcd. for C~23~H~22~ClN~5~O~2~ (435.9) C, 63.37; H, 5.09; N, 16.07. Found: C, 63.56; H, 5.14; N, 15.76.

### 6-{\[(4-Methoxybenzyloxy)phenyl\]acetyl}amino-2-chloro-9-propyladenine (***14***) {#Sec18}

Eluent for chromatography CHCl~3~-MeOH 99:1; yield 29%, white solid; m.p. 174--176°C; ^1^H-NMR (DMSO-*d*~6~): δ 0.84 (t, 3H, *J* = 7.4 Hz, CH~2~*CH*~*3*~), 1.82 (m, 2H, *CH*~*2*~CH~3~), 3.73 (s, 3H, CH~3~-O), 3.79 (s, 3H, CH~2~-CO), 4.14 (t, 2H, *J* = 7.0 Hz, N-CH~2~), 4.98 (s, 2H, CH~2~-O), 6.92 (d, 2H, *J* = 8.0 Hz, H-Ph), 6.93 (d, 2H, *J* = 8.4 Hz, H-Ph), 7.24 (d, 2H, *J* = 8.4 Hz, H-Ph), 7.35 (d, 2H, *J* = 8.4 Hz, H-Ph), 8.49 (s, 1H, H-8), 11.15 (s, 1H, NH). Anal. Calcd. for C~24~H~24~ClN~5~O~3~ (465.9) C, 61.87; H, 5.19; N, 15.03. Found: C, 61.99; H, 5.33; N, 14.91.

Biology {#Sec19}
-------

All pharmacological methods followed the procedures as described earlier \[[@CR26]\]. In brief, membranes for radioligand binding were prepared from CHO cells stably transfected with human adenosine receptor subtypes in a two-step procedure. In a first low-speed step (1,000 *g*) cell fragments and nuclei were removed. The crude membrane fraction was sedimented from the supernatant at 100,000 *g*. The membrane pellet was resuspended in the buffer used for the respective binding experiments, frozen in liquid nitrogen and stored at −80°C. For the measurement of adenylyl cyclase activity only one high speed centrifugation of the homogenate was used. The resulting crude membrane pellet was resuspended in 50 mM Tris/HCl, pH 7.4 and immediately used for the cyclase assay.

For radioligand binding at A~1~ adenosine receptors 1 nM \[^3^H\]CCPA was used, whereas 30 and 10 nM \[^3^H\]NECA were used for A~2A~ and A~3~ receptors, respectively. Non-specific binding of \[^3^H\]CCPA was determined in the presence of 1 mM theophylline; in the case of \[^3^H\]NECA 100 pM R-PIA was used. K~i~ values from competition experiments were calculated with the program SCTFIT \[[@CR33]\]. At A~2B~ adenosine receptors inhibition of NECA-stimulated adenylyl cyclase activity was used as a measurement of potency of the new compounds. IC~50~ values from these experiments were converted to K~i~ values with the Cheng and Prusoff equation \[[@CR34]\].
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